ALPK3 Gene Therapy Restores Function in Preclinical Cardiomyopathy Models

Researchers generated an ALPK3 knockout mouse that recapitulated pediatric-onset dilated cardiomyopathy with reduced ejection fraction and disorganized Z-disks. One-time intravenous administration of an ALPK3-expressing vector restored ejection fraction to near-wild-type levels within four weeks and maintained benefit at twelve weeks. Parallel experiments used CRISPR-corrected and patient iPSC lines carrying the same ALPK3 variant; engineered heart tissues showed normalized force generation and calcium handling after gene addition. The team then applied the Geneformer foundation model to predict ALPK3 rescue of TTN-truncating and MYH7 variants, identifying overlapping downstream proteostasis nodes.

The work extends beyond ALPK3-specific disease by proposing a convergent mechanism in which ALPK3 acts as a quality-control kinase for multiple sarcomeric proteins. This offers a potential single-target approach for up to 25 percent of dilated cardiomyopathy cases currently lacking disease-modifying options. However, the data remain confined to rodent and two-dimensional tissue models; durability, immunogenicity, and off-target cardiac or hepatic effects were not assessed beyond twelve weeks.

Next steps require dose-ranging studies in larger mammals, GMP vector toxicology, and IND-enabling safety packages before first-in-human dosing. Regulatory precedent from approved AAV cardiomyopathies will shape endpoints focused on change in left-ventricular ejection fraction rather than surrogate biomarkers alone.